1. Scrip
  2. >>R&D

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

 
• By Anju Ghangurde

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

molnupiravir
Spotlight On Molnupiravir Trials • Source: Alamy

Amid buoyant expectations about the prospects of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s molnupiravir in COVID-19 following some standout data, two Indian firms including licensee Aurobindo Pharma Limited have sought to stop Phase III studies for the investigational oral antiviral in patients with moderate disease creating a flutter in the country.

Things were further compounded when a report quoted an unnamed official in the Indian regulatory system as saying that the antiviral had not shown "significant efficacy" against moderate COVID-19,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.